This Sleazy GLP-1 Prescription Site Is Using Deepfaked "Before-and-After" Photos of Fake Patients, and Running Ads Showing AI-Generated Ozempic Boxes
In the cash grab for patients eager to get on GLP-1 weight loss drugs like Ozempic, startups are getting so sloppy that their marketing materials look like unintentional parody.
Consider MEDVi, an online prescription hub for GLP-1s. The company wants you to know that it's "serious" about helping you lose weight, according to its website, which entreats visitors to join "50,000+ MEDVi patients" who have turned to the service for weight loss help. That help, it says, comes in the form of "personalized care" and "highly effective weight loss medications," which it characterizes later as "doctor-approved." At a subscription starting price of under $200 with "no insurance required," it adds, it's a "budget-friendly" semaglutide option.
To drive its sales pitch home, MEDVi's website is packed with images of happy-looking, smiling people; the women in the smoothed-over pictures each wear sports bras in trendy colors, while the grinning men are decked out in T-shirts. There's also a slew of alleged customer success stories, which the company claims are from actual MEDVi patients.
"Sometimes you have to see it to believe it," reads a blurb of copy, alongside a series of bef0re-and-after weight loss photos. "GLP-1 medication can be life-changing and improves mood, sleep, energy and longevity. Photos, testimonials and results are from MEDVi patients."
Except, we couldn't help but notice, none of these alleged patients are real. Each image in the smiling, sports-bra'd crowd appears to have been generated from scratch using AI — and the before-and-after photos, more insidiously, are eerily convincing deepfakes, seemingly generated by lifting existing images of real people from across the web and using AI to alter their faces.
MEDVi's site represents layers of sophisticated trickery that, while previously much more difficult, have been made incredibly accessible through easy-to-use text and image generators and deepfake tools. As profiteers race to flood the web with disorienting AI-powered content, including around buzzy products like GLP-1 meds, the eternal advice to not believe everything you read — and now, everything you see — online is now more urgent than ever.
We first came across MEDVi in a deeply mangled digital advertisement found at the foot of a local news article showcasing a clearly AI-generated image of a box of Ozempic. To say nothing of the fact that the image used looks absolutely nothing like a real box of Ozempic, the AI-drawn box is covered with AI artifacts like twisted, gibberish letters, and includes a legume-like logo bearing no resemblance to the real logo used by Ozempic maker Novo Nordisk, which features an Apis bull.
"Solution fo [sic] injection," reads one prominent piece of text on the ersatz box, while another claims that the package contains a "solutån [sic] for injection in pre-filled pen."
"O)zenpic," reads a garbled and incorrectly-spelled Ozempic logo on the side of the box.
Intrigued by the blatancy of the ad's AI slop even in the heavily scrutinized world of pharmaceuticals, we decided to explore further.
Upon clicking the link, we were greeted by the website's first round of AI-generated people — who, though almost convincing, bear signs of AI-generation, like oddly-smooth curls and ears that blend mysteriously into the side of their head.
Just underneath these images, MEDVi includes a rotating list of logos belonging to websites and news publishers, ranging from health hubs like Healthline to reputable publications like The New York Times, Bloomberg, and Forbes, among others — suggesting that MEDVi is reputable enough to have been covered by mainstream publications.
Forbes, we found, did include MEDVi in a roundup of "Best Weight Loss Injections Of 2025," where it earned a "very good" rating of "9.4." The article appeared in Forbes Health, and includes a disclaimer noting that the page's content was "created independently from the Forbes Health Editorial team."
But otherwise, there was no sign of MEDVi coverage in the New York Times, Bloomberg, or the other outlets it mentioned. The only other remotely mainstream news coverage we could find of the company was in an US Weekly article from earlier this month, titled "6 Affordable GLP-1 Solutions After the FDA Bans Generic Medications" that also circulated on Yahoo. (Both the Forbes Health and US Weekly articles were affiliate content, meaning they were created outside of normal editorial channels, and the outlets earn money when readers click the links on the page.)
Perhaps nothing about MEDVi's site, though, is as egregious as its alleged patient before-and-after images.
Under text telling possible customers that the "results speak for themselves," MEDVi features side-by-side pictures of three purported patients: "Sandra K," "Michael P," and "Melissa C."
Contrasted with the stock photo-esque images featured elsewhere on the page, these images looked much less uncanny. Their bodies had more distinct, lifelike details, and objects and lettering seen in the background looked genuine. And when we dug through web searches to see if the images existed elsewhere, we realized that's because the photos of dramatic weight loss were indeed real. At least, from the neck down.
What appears to have happened is that the sloperators behind MEDVi took images that had already been floating around the web for years, and used AI-powered deepfake tech to convincingly alter their faces.
Take the side-by-side images of "Michael P," who MEDVi claims lost 48 pounds over just five months. We were able to find the original image in a Daily Mail article from 2018 — before semaglutide was even approved for weight loss purposes — that featured before-and-after photos of people who quit drinking, which was itself based on an undated Bored Panda article of "Before & After Pics That Show What Happens When You Stop Drinking."
Per Bored Panda and the Daily Mail, the man in the original picture is a Redditor who posts fitness and sobriety content under the username u/iDoneDo. The Daily Mail article timestamps the Redditor's weight loss journey as occurring between 2016 and 2017, which we confirmed by finding u/iDoneDo's original Reddit post.
That ages the image to long before the GLP-1 craze kicked off — and before AI started to fill the web with synthetic and deepfaked content.
Web searches for the other alleged patients yielded similar results: inspirational weight-loss imagery that's drifted around the web for years, and altered to disguise the actual people in the images as fake MEDVi customers.
To bolster its feigned legitimacy, MEDVi's site flaunts a lineup of doctors — full names and headshots included — that the startup claims to have partnered with.
"MEDVi physicians are here to guide you every step of the way," reads the webpage, "bringing both their expertise and genuine care to keep you supported.
When we searched for their names and images of these doctors, we discovered that they were, in fact, real medical professionals with LinkedIn pages, personal websites, and clear work histories. But to our surprise, these searches also returned yet another sketchy website for GLP-1 drugs. This one is called NuHuman, and offers a similar service, though it seems to be targeted specifically at the Chicago area. NuHuman's website is also crawling with AI slop, though once again features the same lineup of very real doctors.
We contacted each doctor to ask if they could confirm their involvement with MEDVi and NuHuman. We heard back from one of those medical professionals at the time of publishing, an osteopathic medicine practitioner named Tzvi Doron, who insisted that he had nothing to do with either company and "[needs] to have them remove me from their sites."
We also reached out to MEDVi, which didn't respond. When we tried to reach out to NuHuman with the site's listed email, the message bounced back.
We did find some Reddit comments, though, warning other netizens to steer clear of MEDVi, claiming serious allegations of possible HIPPA violations, shady billing practices, and even damaged vials of seemingly bogus drugs causing physical harm.
AI is making the web weirder and muddier than ever. And though MEDVi promises that "sometimes you have to see it to believe it," in our burgeoning AI-powered web, that's no longer the case.
More on AI slop: Slop Farmer Boasts About How He Uses AI to Flood Social Media With Garbage to Trick Older Women

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hill
32 minutes ago
- The Hill
How long does it take weight loss drugs to work?
Weight loss medications like Ozempic and Wegovy have become increasingly popular over the past few years. For those who are looking into using a weight loss drug, how fast they work often comes into question. While the timeline for noticeable changes varies from person to person, people have often noticed changes in their appetite and weight within the first few weeks of use. According to the Mayo Clinic, most weight loss occurs within the first four to five months of use. Long-term use of weight loss drugs can lead to sustained weight decreases and improvements in overall metabolic health but must be paired with healthy eating and exercise. There are a few factors that can contribute to how quickly weight loss drugs can work for each individual, like metabolism and following the treatment plan. People with a higher metabolism are more likely to see results faster from weight loss drugs compared to those with a lower metabolic rate. Lifestyle factors like dietary habits, exercise routines, adequate sleep and stress management also play a role in the speed at which weight loss drugs work. Since the drugs can suppress your appetite, it can be challenging to get proper nutrition and possibly lead to side effects. Doctors say to manage any side effects, you should follow a nutritionally balanced diet and drink enough fluids.
Yahoo
4 hours ago
- Yahoo
Stevanato Group S.p.A. (STVN): A Bull Case Theory
We came across a bullish thesis on Stevanato Group S.p.A. (STVN) on Best Anchor Stocks' Substack. In this article, we will summarize the bulls' thesis on STVN. Stevanato Group S.p.A. (STVN)'s share was trading at $22.61 as of 22nd May. STVN's trailing and forward P/E were 43.55 and 37.45 respectively according to Yahoo Finance. A biopharmaceutical facility with technicians working on a manufacturing line of treatments and preventions. Stevanato's recent earnings release highlighted a sharp return to growth, with Q1 revenue up 9% to €256.6 million—far ahead of expectations—driven primarily by strong performance in its high-value products (HVPs) and the ramp-up of new facilities in Latina and Fishers. Despite this impressive beat, the stock gave up early gains, staying true to its volatile trading pattern. However, the real story lies in Stevanato's compelling margin expansion potential and what appears to be sandbagged guidance. Margins improved meaningfully in Q1, yet remain artificially depressed due to underutilized vial capacity, dilutive effects from new plant ramp-ups, and a still-recovering engineering division. Net income grew 41% on just 9% revenue growth, illustrating the leverage embedded in the model. Management's commentary suggests that over time, as engineering margins normalize and the HVP mix continues to increase—especially with major projects like Ez-Fill cartridges for likely customers such as Novo Nordisk—the company could unlock over 1,000 basis points in margin expansion. Furthermore, current HVP gross margins are estimated to be double those of bulk products, signaling substantial upside. While guidance for 2025 was only modestly raised and Adjusted EBITDA lowered slightly due to tariffs, this conservatism appears more like strategic sandbagging than a real slowdown. Based on Q1 results and seasonal trends, full-year revenue could exceed management's guidance by 2.5%, implying double-digit growth is very much in reach. With expanding margins, a durable growth runway driven by mix shift and replacement demand, and strategic positioning in the U.S., Stevanato offers a long-term upside narrative not reflected in current valuation multiples. Stevanato Group S.p.A. (STVN) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 11 hedge fund portfolios held STVN at the end of the fourth quarter which was 11 in the previous quarter. While we acknowledge the risk and potential of STVN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than STVN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Yahoo
8 hours ago
- Yahoo
China launches Tianwen-2 space probe to collect samples from asteroid near Mars
China has launched a space probe that will travel to an asteroid near Mars to collect samples and find potential "groundbreaking" results. The Tianwen-2 probe launched Thursday from the Xichang Satellite Launch Center in southwest China's Sichuan Province aboard the workhorse Long March 3-B rocket, according to the China National Space Administration (CNSA). The target of the Tianwen-2 will be different from its predecessor, the Tianwen-1, which launched a year ago and landed on Mars. Tianwen-2 will be aiming for the asteroid 2016 HO3, which is also known as 469219 Kamoʻoalewa, to bring back samples. China's Secret Weapon In The Space Race Is Already Hurting Us The proposed 10-year plan would involve more than just this space mission as China continues to look to expand into space. Read On The Fox News App Zhang Rongqiao, chief designer of the Tianwen-1, told China Central Television he plans to implement the "Tianwen-3" Mars sampling return mission in 2028, while the "Tianwen-4" will head toward Jupiter. According to The Associated Press, the asteroids, chosen for their relatively stable orbits, will hopefully offer clues about the formation of Earth, such as the origins of water. Us Prepares To Deorbit International Space Station Amid China Competition Samples from 2016HO3 are due to be returned in about two years. Even if the CNSA is going to distribute these samples to international partners like they have on previous missions, NASA wouldn't be able to receive any samples. A law passed in 2011, known as the Wolf Amendment, restricts NASA from having any cooperation with the CNSA. China also operates the three-person Tiangong, or "Heavenly Palace," space station. This gives China a step in the right direction to become a major force in the exploration of space. Its permanent station was created after being excluded from the International Space Station over U.S. national security concerns. The Associated Press contributed to this storyOriginal article source: China launches Tianwen-2 space probe to collect samples from asteroid near Mars